sellWeak cluster of 210b5-1 plan
Paul T Quinlan sold $69k of CBAY
General Counsel at CymaBay Therapeutics, Inc.. 5,000 shares at an average of $13.76, traded Oct 16, 2023, filed Oct 18, 2023.
Warning score
16Value
$69k
5,000 shares
Holdings after
0
-100% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet
Score components
- +15RoleOfficer
- +8Trade size$69k at market
- +20Share of holdings soldSold 100% of holdings
- +8Cluster2 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Rows in this filing
Every transaction in Form 4 0001062993-23-019547, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Oct 16, 2023 | MOption exercise Common Stock | +5,000 | $2.94 | $15k | 5,000 | Oct 18, 2023 |
| Oct 16, 2023 | SOpen-market sale Common Stock10b5-1 | -5,000 | $13.76 | $69k | 0 | Oct 18, 2023 |
| Oct 16, 2023 | MOption exercise Employee Stock Option (right to buy)derivative | -5,000 | $0.00 | $0 | 122,000 | Oct 18, 2023 |
Related signals
Other insiders at CymaBay Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 33Weak | CymaBay Therapeutics, Inc. | Charles McWherter President of R&D | $243k 11,332 shares | -57% | |
| 25Weak | CymaBay Therapeutics, Inc. | Paul T Quinlan General Counsel | $110k 5,000 shares | -100% | |
| 32Weak | CymaBay Therapeutics, Inc. | Daniel Menold Vice President, Finance | $473k 21,497 shares | -215% | |
| 25Weak | CymaBay Therapeutics, Inc. | Janet Dorling director | $120k 6,000 shares | -100% | |
| 40Moderate | CymaBay Therapeutics, Inc. | Sujal Shah Chief Executive Officer | $1.3M 64,865 shares | -28% | |
| 24Weak | CymaBay Therapeutics, Inc. | Paul T Quinlan General Counsel | $87k 5,000 shares | -100% | |
| 22Weak | CymaBay Therapeutics, Inc. | Charles McWherter President of R&D | $207k 11,342 shares | -43% | |
| 25Weak | CymaBay Therapeutics, Inc. | Janet Dorling director | $107k 7,000 shares | -100% | |
| 40Moderate | CymaBay Therapeutics, Inc. | Sujal Shah Chief Executive Officer | $1.0M 64,863 shares | -30% | |
| 27Weak | CymaBay Therapeutics, Inc. | Charles McWherter President of R&D | $306k 21,743 shares | -59% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.